147 related articles for article (PubMed ID: 37515801)
1. How has the COVID-19 pandemic affected our rheumatology patients using biological/targeted DMARDs?
Gulle S; Erez Y; Karakas A; Yuce Inel T; Kocaer SB; Demirci Yildirim T; Can G; Sari I; Birlik M; Onen F
J Infect Dev Ctries; 2023 Jul; 17(7):944-952. PubMed ID: 37515801
[TBL] [Abstract][Full Text] [Related]
2. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries.
Glintborg B; Di Giuseppe D; Wallman JK; Nordström DC; Gudbjornsson B; Hetland ML; Askling J; Grondal G; Sokka T; Provan SA; Michelsen B; Kristianslund EK; Dreyer L; Love TJ; Lindström U
Ann Rheum Dis; 2023 Jun; 82(6):820-828. PubMed ID: 36813538
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of patients with COVID-19 and inflammatory rheumatic diseases receiving biological/targeted therapy.
Pehlivan Ö; Aydin T
Ann Saudi Med; 2022; 42(3):155-164. PubMed ID: 35658585
[TBL] [Abstract][Full Text] [Related]
4. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
5. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
6. Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Bhushan V; Lester S; Briggs L; Hijjawi R; Shanahan EM; Pontifex E; Ninan J; Hill C; Cai F; Walker J; Goldblatt F; Wechalekar MD
Front Med (Lausanne); 2021; 8():708168. PubMed ID: 34646840
[No Abstract] [Full Text] [Related]
7. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
8. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort.
Ciurea A; Papagiannoulis E; Bürki K; von Loga I; Micheroli R; Möller B; Rubbert-Roth A; Andor M; Bräm R; Müller A; Dan D; Kyburz D; Distler O; Scherer A; Finckh A
Ann Rheum Dis; 2021 Feb; 80(2):238-241. PubMed ID: 32963052
[TBL] [Abstract][Full Text] [Related]
9. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
[TBL] [Abstract][Full Text] [Related]
10. Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
Kalweit M; Burden AM; Boedecker J; Hügle T; Burkard T
PLoS Comput Biol; 2023 Jun; 19(6):e1011073. PubMed ID: 37267387
[TBL] [Abstract][Full Text] [Related]
11. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia.
Fletcher A; Lassere M; March L; Hill C; Barrett C; Carroll G; Buchbinder R
Rheumatology (Oxford); 2022 Oct; 61(10):3939-3951. PubMed ID: 35094044
[TBL] [Abstract][Full Text] [Related]
12. Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis.
Whittle SL; Glennon V; Johnston RV; Avery JC; Bell JS; Brennan SE; Fong C; Hissaria P; Horgan B; O'Neill S; Pisaniello HL; Trevena L; Whittaker GA; Wluka A; Buchbinder R
Intern Med J; 2022 Oct; 52(10):1799-1805. PubMed ID: 35567366
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis.
Zhao SS; Kearsley-Fleet L; Bosworth A; Watson K; ; Hyrich KL
Rheumatology (Oxford); 2022 Nov; 61(12):4678-4686. PubMed ID: 35357421
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of Covid-19 in patients with rheumatic diseases and the effects of the pandemic on rheumatology outpatient care: A single-centre experience from Turkey.
Batıbay S; Koçak Ulucaköy R; Özdemir B; Günendi Z; Göğüş FN
Int J Clin Pract; 2021 Sep; 75(9):e14442. PubMed ID: 34105856
[TBL] [Abstract][Full Text] [Related]
15. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic.
Kalyoncu U; Pehlivan Y; Akar S; Kaşifoğlu T; Kimyon G; Karadağ Ö; Dalkılıç HE; Ertenli Aİ; Kılıç L; Ersözlü D; Bes C; Emmungil H; Mercan R; Ediboğlu ED; Kanıtez N; Bilgin E; Çolak S; Koca SS; Gönüllü E; Küçükşahin O; Coşkun N; Yağız B; Kiraz S
Turk J Med Sci; 2021 Aug; 51(4):1615-1623. PubMed ID: 33611869
[TBL] [Abstract][Full Text] [Related]
16. Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience.
Migkos MP; Kaltsonoudis E; Pelechas E; Drossou V; Karagianni PG; Kavvadias A; Voulgari PV; Drosos AA
Rheumatol Int; 2021 May; 41(5):903-909. PubMed ID: 33655421
[TBL] [Abstract][Full Text] [Related]
17. Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland.
Burkard T; Vallejo-Yagüe E; Hügle T; Finckh A; Burden AM
BMJ Open; 2022 Mar; 12(3):e056352. PubMed ID: 35292498
[TBL] [Abstract][Full Text] [Related]
18. Effects of biologic and target synthetic disease-modifying anti-rheumatic drugs on sarcopenia in spondyloarthritis and rheumatoid arthritis: a systematic review and meta-analysis.
Ben Tekaya A; Mehmli T; Ben Sassi M; Teyeb Z; Bouden S; Rouached L; Mahmoud I; Dziri C; Abdelmoula L
Clin Rheumatol; 2023 Apr; 42(4):979-997. PubMed ID: 36462127
[TBL] [Abstract][Full Text] [Related]
19. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.
Michelena X; Borrell H; López-Corbeto M; López-Lasanta M; Moreno E; Pascual-Pastor M; Erra A; Serrat M; Espartal E; Antón S; Añez GA; Caparrós-Ruiz R; Pluma A; Trallero-Araguás E; Barceló-Bru M; Almirall M; De Agustín JJ; Lladós J; Julià A; Marsal S
Semin Arthritis Rheum; 2020 Aug; 50(4):564-570. PubMed ID: 32425260
[TBL] [Abstract][Full Text] [Related]
20. Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010.
Ichinose K; Shimizu T; Umeda M; Fukui S; Nishino A; Koga T; Kawashiri SY; Iwamoto N; Tamai M; Nakamura H; Sato S; Origuchi T; Kawakami A
J Immunol Res; 2018; 2018():6259010. PubMed ID: 30186881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
